{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:23:29Z","timestamp":1792002209687,"version":"4.4.0"},"reference-count":91,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>AF is the most common arrhythmia in clinical practice, with a large preponderance in the older (&gt;75 years) adult population. Stroke is the most feared complication of AF, with huge corresponding morbidity and mortality. Anticoagulation is the mainstay for stroke prevention in AF, but is commonly underutilised in clinical practice due to the fear of intracerebral bleeding. Bleeding is the primary concern in older patients with conventional vitamin K antagonist use. Direct oral anticoagulants (DOACs) have been used for a decade in clinical practice and have been found to reduce major bleeds. The advantages of DOAC use in older patients include obviating the need for intermittent international normalised ratio monitoring, fewer drug interactions and reduction in intracerebral haemorrhage. The disadvantages of DOAC use include older patients having to take multiple doses per day and a lack of a universal antidote, as opposed to vitamin K antagonists. However, a lack of head-to-head trials among DOACs and specific randomised controlled trials in older patients preclude a definite conclusion regarding the ideal DOAC that should be used in the older population. Factor XI inhibition is an emerging approach for oral anticoagulation that holds promise for dissociating thrombosis from haemostasis. This provides an additional avenue for reducing bleeding in the older adult population.<\/jats:p>","DOI":"10.15420\/ecr.2024.17","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:09:33Z","timestamp":1740118173000},"source":"Crossref","is-referenced-by-count":16,"title":["Direct Oral Anticoagulant Use in Older Adults with Atrial Fibrillation: Challenges and Solutions"],"prefix":"10.15420","volume":"20","author":[{"given":"Monika","family":"Bhandari","sequence":"first","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshyaya","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravesh","family":"Vishwakarma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, King George\u2019s Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Di Renzo","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8421-5065","authenticated-orcid":false,"given":"Ferdinando","family":"Iellamo","sequence":"additional","affiliation":[{"name":"Division of Cardiology and CardioLab, Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahid","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Pathology, King George\u2019s Medical University, Lucknow, Uttar\u00a0Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-2621","authenticated-orcid":false,"given":"Marco Alfonso","family":"Perrone","sequence":"additional","affiliation":[{"name":"Division of Cardiology and CardioLab, Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Bencivenga L,\u00a0Komici K,\u00a0Nocella P, et\u00a0al. Atrial fibrillation in the elderly: a risk factor beyond stroke. Ageing Res Rev 2020;61:101092. https:\/\/doi.org\/10.1016\/j.arr.2020.101092; PMID:\u00a032479927.","DOI":"10.1016\/j.arr.2020.101092"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Hanon O,\u00a0Assayag P,\u00a0Belmin J, et\u00a0al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis 2013;106:303\u201323. https:\/\/doi.org\/10.1016\/j.acvd.2013.04.001; PMID:\u00a023769405.","DOI":"10.1016\/j.acvd.2013.04.001"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(16)30506-2; PMID:\u00a027431356.","DOI":"10.1016\/S0140-6736(16)30506-2"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 2012;43:3442\u201353. https:\/\/doi.org\/10.1161\/STR.0b013e318266722a; PMID:\u00a022858728.","DOI":"10.1161\/str.0b013e318266722a"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124. https:\/\/doi.org\/10.1136\/bmj.d124; PMID:\u00a021282258.","DOI":"10.1136\/bmj.d124"},{"key":"ref5","unstructured":"Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardiothoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2020;42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612; PMID:\u00a032860505."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021;23:1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065; PMID:\u00a033895845.","DOI":"10.1093\/europace\/euab157"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857\u201367. https:\/\/doi.org\/10.7326\/0003-4819-146-12-200706190-00007; PMID:\u00a017577005.","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Rash A, Downes T, Portner R, et al. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151\u20136. https:\/\/doi.org\/10.1093\/ageing\/afl129; PMID:\u00a017175564.","DOI":"10.1093\/ageing\/afl129"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Mant J, Hobbs FDR, Fletcher K, et al. BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 2007;370:493\u2013503. https:\/\/doi.org\/10.1016\/S0140-6736(07)61233-1; PMID:\u00a017693178.","DOI":"10.1016\/s0140-6736(07)61233-1"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006;367:1903\u201312. https:\/\/doi.org\/10.1016\/s0140-6736(06)68845-4; PMID:\u00a016765759.","DOI":"10.1016\/s0140-6736(06)68845-4"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"January CT, Wann LS, Calkins H, et al. AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2019;140:e125\u201351. https:\/\/doi.org\/10.1161\/CIR.0000000000000665; PMID:\u00a030686041.","DOI":"10.1161\/CIR.0000000000000719"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012;126:2381\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.115410; PMID:\u00a023071159.","DOI":"10.1161\/circulationaha.112.115410"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Edholm K, Ragle N, Rondina MT. Anti-thrombotic management of atrial fibrillation in the elderly. Med Clin North Am 2015;99:417\u201330. https:\/\/doi.org\/10.1016\/j.mcna.2014.11.012; PMID:\u00a025700592.","DOI":"10.1016\/j.mcna.2014.11.012"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Barco S, Cheung YW, Eikelboom JW, Coppens M. New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol 2013;26:215\u201324. https:\/\/doi.org\/10.1016\/j.beha.2013.07.011; PMID:\u00a023953909.","DOI":"10.1016\/j.beha.2013.07.011"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Lip GYH, Al-Khatib SM, Cosio FG, et al. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and a current therapeutic approaches? J Am Heart Assoc 2014;3:e001179. https:\/\/doi.org\/10.1161\/JAHA.114.001179; PMID:\u00a025164944.","DOI":"10.1161\/jaha.114.001179"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Caldeira D, Nunes-Ferreira A, Rodrigues R, et al. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr 2019;81:209\u201314. https:\/\/doi.org\/10.1016\/j.archger.2018.12.013; PMID:\u00a030612074.","DOI":"10.1016\/j.archger.2019.04.008"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110:453\u201360. https:\/\/doi.org\/10.1016\/j.amjcard.2012.03.049; PMID:\u00a022537354.","DOI":"10.1016\/j.amjcard.2012.03.049"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Giugliano RP. Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. Eur Heart J Suppl 2022;24(Suppl A):A1\u2013A10. https:\/\/doi.org\/10.1093\/eurheartj\/suab150; PMID:\u00a035185404.","DOI":"10.1093\/eurheartj\/suab150"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907; PMID:\u00a024251359.","DOI":"10.1056\/NEJMoa1310907"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2013;127:634\u201340. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.115386; PMID:\u00a023271794.","DOI":"10.1161\/circulationaha.112.115386"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the Aristotle trial. Eur Heart J 2014;35:1864\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehu046; PMID:\u00a024561548.","DOI":"10.1093\/eurheartj\/ehu046"},{"key":"ref22","unstructured":"Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014;63:891\u2013900. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.013; PMID:\u00a024315894."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022;145:242\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355; PMID:\u00a034985309.","DOI":"10.1161\/CIR.0000000000001058"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Rutherford OW, Jonasson C, Ghanima W, et al. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. Heart 2022;108:345\u201352. https:\/\/doi.org\/10.1136\/heartjnl-2020-318753; PMID:\u00a033975877.","DOI":"10.1136\/heartjnl-2020-318753"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Polymeris AA, Macha K, Paciaroni M, et al. Oral anticoagulants in the oldest old with recent stroke and atrial fibrillation. Ann Neurol 2022;91:78\u201388. https:\/\/doi.org\/10.1002\/ana.26267; PMID:\u00a034747514.","DOI":"10.1002\/ana.26267"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Chao TF, Liu CJ, Lin YJ, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 2018;138:37\u201347. https:\/\/DOI.ORG\/10.1161\/CIRCULATIONAHA.117.031658. PMID:\u00a029490992.","DOI":"10.1161\/CIRCULATIONAHA.117.031658"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Lip GYH, Keshishian AV, Kang AL, et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med 2021\u00a0;289:42\u201352. https:\/\/doi.org\/10.1111\/joim.13140; PMID:\u00a032602228.","DOI":"10.1111\/joim.13140"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Guo WQ, Chen XH, Tina XY, Li L. Differences in gastrointestinal profile among novel oral anticoagulants: evidence from a network meta-analysis. Clin Epidemiol 2019;11:911\u201321. https:\/\/doi.org\/10.2147\/CLEP.S219335; PMID:\u00a031632152.","DOI":"10.2147\/clep.s219335"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Grymonprez M, Steurbaut S, De Backer TL, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol 2020;11:583311. https:\/\/doi.org\/10.3389\/fphar.2020.583311; PMID:\u00a033013422.","DOI":"10.3389\/fphar.2020.583311"},{"key":"ref30","unstructured":"Lee KH, Chen YF, Yeh WY, et al. Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis. Age Ageing 2022;51:afac292. https:\/\/doi.org\/10.1093\/ageing\/afac292; PMID:\u00a036571776."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Bai Y, Guo SD, Deng H, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age Ageing 2018;47:9\u201317. https:\/\/doi.org\/10.1093\/ageing\/afx103; PMID:\u00a028985259.","DOI":"10.1093\/ageing\/afx103"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Erdem G, Esme M, Do\u011fu BB. Systematic review and meta-analysis of randomized controlled trials on safety and effectiveness of oral anticoagulants for atrial fibrillation in older people. Ir J Med Sci 2022;191:2517\u201323. https:\/\/doi.org\/10.1007\/s11845-021-02891-x; PMID:\u00a035060062.","DOI":"10.1007\/s11845-021-02891-x"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Mitchell A, Watson MC, Welsh T, McGrogan A. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. J Clin Med 2019;8:554. https:\/\/doi.org\/10.3390\/jcm8040554; PMID:\u00a031022899.","DOI":"10.3390\/jcm8040554"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Doni K, B\u00fchn S, Weise A, et al. Safety outcomes of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials. GeroScience 2024;46:923\u201344. https:\/\/doi.org\/10.1007\/s11357-023-00825-2; PMID:\u00a037261677.","DOI":"10.1007\/s11357-023-00825-2"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Malik AH, Yandrapalli S, Aronow WS, et al. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. Am J Cardiol 2019;123:2051\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2019.02.060; PMID:\u00a030982541.","DOI":"10.1016\/j.amjcard.2019.02.060"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Chan YH, See LC, Tu HT, et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc 2018;7:e008150. https:\/\/DOI.ORG\/10.1161\/JAHA.117.008150; PMID:\u00a029622587.","DOI":"10.1161\/jaha.117.008150"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Rutherford OW, Jonasson C, Ghanima W, et al. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2020;6:75\u201385. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz086; PMID:\u00a031942972.","DOI":"10.1093\/ehjcvp\/pvz086"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 2016;150:1302\u201312. https:\/\/doi.org\/10.1016\/j.chest.2016.07.013; PMID:\u00a027938741.","DOI":"10.1016\/j.chest.2016.07.013"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Cohen AT, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLOS ONE 2015;10:e0144856. https:\/\/doi.org\/10.1371\/journal.pone.0144856; PMID:\u00a026716830.","DOI":"10.1371\/journal.pone.0144856"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Lip GYH, Keshishian AV, Zhang Y, et al. Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. JAMA Netw Open 2021;4:e2120064. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.20064; PMID:\u00a034398204.","DOI":"10.1001\/jamanetworkopen.2021.20064"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020;383:1735\u201345. https:\/\/doi.org\/10.1056\/NEJMoa2012883; PMID:\u00a032865374.","DOI":"10.1056\/nejmoa2012883"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Cheng MH, Chang SF. Frailty as a risk factor for falls among community dwelling people: evidence from a meta-analysis. J Nurs Scholarsh 2017;49:529\u201336. https:\/\/doi.org\/10.1111\/jnu.12322; PMID:\u00a028755453.","DOI":"10.1111\/jnu.12322"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Makizako H, Shimada H, Doi T, et al. Impact of physical frailty on disability in community-dwelling older adults: a prospective cohort study. BMJ Open 2015;5:e008462. https:\/\/doi.org\/10.1136\/bmjopen-2015-008462; PMID:\u00a026338685.","DOI":"10.1136\/bmjopen-2015-008462"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Wolff A, Shantsila E, Lip GYH, Lane DA. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. Age Ageing 2015;44:874\u20138. https:\/\/doi.org\/10.1093\/ageing\/afv071; PMID:\u00a026082176.","DOI":"10.1093\/ageing\/afv071"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med 2007;120:481\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2007.01.026; PMID:\u00a017524745.","DOI":"10.1016\/j.amjmed.2007.01.026"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Hylek EM. Contra: \u201cwarfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation\u201d. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost 2008;100:16\u20137. https:\/\/DOI.ORG\/10.1160\/TH08-06-0343; PMID:\u00a018612532.","DOI":"10.1160\/th08-06-0343"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol 2016;67:2913\u201323. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.581; PMID:\u00a027339487.","DOI":"10.1016\/j.jacc.2016.03.581"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Verheugt FWA, Gao H, Al Mahmeed W, et al. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J 2018\u00a0;39:464\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehx730; PMID:\u00a029281086.","DOI":"10.1093\/eurheartj\/ehx730"},{"key":"ref49","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1007432; PMID:\u00a021309657."},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Ng KH, Shestakovska O, Connolly SJ, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the Averroes trial. Age Ageing 2016;45:77\u201383. https:\/\/doi.org\/10.1093\/ageing\/afv156; PMID:\u00a026590293.","DOI":"10.1093\/ageing\/afv156"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2005.04.017; PMID:\u00a016504638.","DOI":"10.1016\/j.ahj.2005.04.017"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) Study. J Am Coll Cardiol 2011;58:395\u2013401. https:\/\/doi.org\/10.1016\/j.jacc.2011.03.031; PMID:\u00a021757117.","DOI":"10.1016\/j.jacc.2011.03.031"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093\u2013100. https:\/\/doi.org\/10.1378\/chest.10-0134; PMID:\u00a020299623.","DOI":"10.1378\/chest.10-0134"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open 2017;7:e017157. https:\/\/doi.org\/10.1136\/bmjopen-2017-017157; PMID:\u00a029273652.","DOI":"10.1136\/bmjopen-2017-017157"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"O\u2019Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015;36:3258\u201364. https:\/\/doi.org\/10.1093\/eurheartj\/ehv476; PMID:\u00a026424865.","DOI":"10.1093\/eurheartj\/ehv476"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2015;38:555\u201361. https:\/\/doi.org\/10.1002\/clc.22435; PMID:\u00a026418409.","DOI":"10.1002\/clc.22435"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018;118:2171\u201387. https:\/\/doi.org\/10.1055\/s-0038-1675400; PMID:\u00a030376678.","DOI":"10.1055\/s-0038-1675400"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Gao X, Cai X, Yang Y, et al. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 2021;8:757087. https:\/\/doi.org\/10.3389\/fcvm.2021.757087; PMID:\u00a034881309.","DOI":"10.3389\/fcvm.2021.757087"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Wang C, Yu Y, Zhu W, et al. Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget 2017\u00a0;8:109703\u201311. https:\/\/doi.org\/10.18632\/oncotarget.19858; PMID:\u00a029312640.","DOI":"10.18632\/oncotarget.19858"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Liu X, Wang S, He W, Guo L. HAS-BLED vs. ORBIT scores in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 2022;9:1042763. https:\/\/doi.org\/10.3389\/fcvm.2022.1042763; PMID:\u00a036684554.","DOI":"10.3389\/fcvm.2022.1042763"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Chao TF, Lip GYH, Lin YJ, et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018;118:768\u201377. https:\/\/doi.org\/10.1055\/s-0038-1636534; PMID:\u00a029510426.","DOI":"10.1055\/s-0038-1636534"},{"key":"ref62","unstructured":"Annoni G, Mazzola P. Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants? J Geriatr Cardiol 2016;13:226\u201332. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2016.03.010; PMID:\u00a027103917."},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Mitchell A, Snowball J, Welsh TJ, et al. Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. BMC Med 2021;19:189. https:\/\/doi.org\/10.1186\/s12916-021-02067-5; PMID:\u00a034461899.","DOI":"10.1186\/s12916-021-02067-5"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Gage BF, Birman-Deych E, Kerzner R, et al. Incidence of intracranial hemorrhage in patient with atrial fibrillation who are prone to fall. Am J Med 2005;118:612\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2005.02.022; PMID:\u00a015922692.","DOI":"10.1016\/j.amjmed.2005.02.022"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation 2020;141:1384\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044059; PMID:\u00a032160801.","DOI":"10.1161\/circulationaha.119.044059"},{"key":"ref66","unstructured":"US Food and Drug Administration. Apixaban package insert. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf (accessed 12 September 2023)"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Fatima H, Nwankwo I, Anam M, et al. Safety and efficacy of Apixaban vs warfarin in patients with Stage 4 and 5 chronic kidney disease: a systematic review. Cureus 2022;14:e30230. https:\/\/doi.org\/10.7759\/cureus.30230; PMID:\u00a036381830.","DOI":"10.7759\/cureus.30230"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Dahal K, Kunwar S, Rijal J, et al. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 2016;149:951\u20139. https:\/\/doi.org\/10.1378\/chest.15-1719; PMID:\u00a026378611.","DOI":"10.1378\/chest.15-1719"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Xu H, Ruff CT, Giugliano RP, et al. Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI-48 trial. J Am Heart Assoc 2016;5:e002587. https:\/\/DOI.ORG\/10.1161\/JAHA.115.002587; PMID:\u00a026908401.","DOI":"10.1161\/jaha.115.002587"},{"key":"ref70","unstructured":"Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2014.02.549; PMID:\u00a024657685."},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.004747; PMID:\u00a021576658.","DOI":"10.1161\/CIRCULATIONAHA.110.004747"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014;130:138\u201346. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005008; PMID:\u00a024895454.","DOI":"10.1161\/CIRCULATIONAHA.113.005008"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med 2011;27:1\u201315. https:\/\/doi.org\/10.1016\/j.cger.2010.08.009; PMID:\u00a021093718.","DOI":"10.1016\/j.cger.2010.08.009"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc 2010;58:681\u20137. https:\/\/doi.org\/10.1111\/j.1532-5415.2010.02764.x; PMID:\u00a020345864.","DOI":"10.1111\/j.1532-5415.2010.02764.x"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Polidoro A, Stefanelli F, Ciacciarelli M, et al. Frailty in patients affected by atrial fibrillation. Arch Gerontol Geriatr 2013\u00a0;57:325\u20137. https:\/\/doi.org\/10.1016\/j.archger.2013.04.014; PMID:\u00a023706973.","DOI":"10.1016\/j.archger.2013.04.014"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Rosas Diaz AN, Troy AL, Kaplinskiy V, et al. Assessment and management of atrial fibrillation in older adults with frailty. Geriatrics (Basel) 2024\u00a0;9:50. https:\/\/doi.org\/10.3390\/geriatrics9020050; PMID:\u00a038667517.","DOI":"10.3390\/geriatrics9020050"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Doody P, Lord JM, Greig CA, Whittaker AC. Frailty: pathophysiology, theoretical and operational definition(s), impact, prevalence, management and prevention, in an increasingly economically developed and ageing world. Gerontology 2023;69:927\u201345. https:\/\/doi.org\/10.1159\/000528561; PMID:\u00a036476630.","DOI":"10.1159\/000528561"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146\u201356. https:\/\/doi.org\/10.1093\/gerona\/56.3.m146; PMID:\u00a011253156.","DOI":"10.1093\/gerona\/56.3.m146"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet 2018;391:1775\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(18)30668-8; PMID:\u00a029706364.","DOI":"10.1016\/s0140-6736(18)30668-8"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Segal JB, Chang HY, Du Y, et al. Development of a claims-based frailty indicator anchored to a well-established frailty phenotype. Med Care 2017;55:716\u201322. https:\/\/doi.org\/10.1097\/MLR.0000000000000729; PMID:\u00a028437320.","DOI":"10.1097\/mlr.0000000000000729"},{"key":"ref81","unstructured":"Steverink N, Slaets J, Schuurmans H, van Lis M. Measuring frailty: developing and testing the GFI (Groningen Frailty Indicator). Gerontologist 2001;41:236\u20137."},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Akashi S, Oguri M, Ikeno E, et al. Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial. JAMA Netw Open 2022;5:e2228500. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.28500; PMID:\u00a035997978.","DOI":"10.1001\/jamanetworkopen.2022.28500"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Kim D, Yang PS, Sung JH, et al. Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. Stroke 2022;53:1873\u201382. https:\/\/doi.org\/10.1161\/STROKEAHA.121.036757; PMID:\u00a035109686.","DOI":"10.1161\/strokeaha.121.036757"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Chan YH, Chao TF, Chen SW, et al. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2023;9:681\u201391. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad058; PMID:\u00a037580139.","DOI":"10.1093\/ehjcvp\/pvad058"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Kim SS, Lee KH, Yoon NS, et al. What is standard dose of rivaroxaban in elderly Asian patients with atrial fibrillation: 20ms versus. 15mg? Clin Appl Thromb Hemost 2021;27:10760296211061148. https:\/\/doi.org\/10.1177\/10760296211061148; PMID:\u00a034786989; PMCID:\u00a0PMC8606923.","DOI":"10.1177\/10760296211061148"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Joosten LPT, van Doorn S, van de Ven PM, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation 2024;149:279\u201389. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066485; PMID:\u00a037634130.","DOI":"10.1161\/CIRCULATIONAHA.124.070172"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Pan KL, Singer DE, Ovbiagele B, et al. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc 2017\u00a0;6:e005835. https:\/\/doi.org\/10.1161\/JAHA.117.005835; PMID:\u00a028720644.","DOI":"10.1161\/jaha.117.005835"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke 2018;49:2933\u201344. https:\/\/doi.org\/10.1161\/STROKEAHA.118.020232; PMID:\u00a030571400.","DOI":"10.1161\/strokeaha.118.020232"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"De Caterina R, Prisco D, Eikelboom JW. Factor XI inhibitors: cardiovascular perspectives. Eur Heart J 2023;44:280\u201392. https:\/\/doi.org\/10.1093\/eurheartj\/ehac464; PMID:\u00a036263776.","DOI":"10.1093\/eurheartj\/ehac464"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Harrington J, Piccini JP, Alexander JH, et al. Clinical evaluation of Factor XIa inhibitor drugs: JACC review topic of the week. J Am Coll Cardiol 2023;81:771\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.057; PMID:\u00a036813377.","DOI":"10.1016\/j.jacc.2022.11.057"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2024.17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:13:18Z","timestamp":1740118398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2024.17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":91,"URL":"https:\/\/doi.org\/10.15420\/ecr.2024.17","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"article-number":"e04"}}